Published on 22/12/2025
How Companion Diagnostics Enable Targeted Patient Stratification
Introduction: The Shift Toward Biomarker-Based Stratification
Companion diagnostics (CDx) are revolutionizing the clinical research and therapeutic landscape by enabling targeted patient stratification. No longer is a one-size-fits-all approach acceptable—biomarker-based stratification ensures patients receive therapies tailored to their genetic, proteomic, or molecular profiles. Whether in clinical trials or routine practice, stratification using CDx improves efficacy, reduces adverse effects, and accelerates regulatory approvals.
This article explores the strategic role of CDx in patient stratification, offering clinical examples, assay formats, and trial design frameworks that leverage predictive biomarker insights.
What Is Patient Stratification?
Patient stratification refers to the process of dividing a patient population into subgroups based on specific characteristics—commonly biomarkers, genetic mutations, or protein expression. The goal is to identify which subgroup is more likely to benefit from a given therapy.
- Predictive Biomarkers: Indicate likely response to therapy (e.g., HER2 for trastuzumab efficacy)
- Prognostic Biomarkers: Indicate disease outcome irrespective of treatment (e.g., BRCA1/2 in breast cancer)
Stratification ensures optimized therapeutic selection, enhancing the clinical trial’s statistical power and real-world outcomes.
Role of Companion Diagnostics in Stratification
Companion diagnostics are in vitro assays developed alongside therapeutics. Their role in stratification includes:
- Identifying biomarker-positive patients eligible for a targeted therapy
- Enabling
FDA defines a CDx as a device that is essential for the safe and effective use of a corresponding therapeutic product. Its clinical relevance must be demonstrated through co-development with the drug.
Case Study: EGFR Mutation Testing in NSCLC
In non-small cell lung cancer (NSCLC), EGFR mutations (e.g., exon 19 deletions or L858R substitution) serve as predictive biomarkers for tyrosine kinase inhibitors (TKIs) like erlotinib or osimertinib. The cobas® EGFR Mutation Test v2 is an FDA-approved CDx for detecting these mutations.
Patient stratification using this test demonstrated:
- Increased progression-free survival (PFS) in biomarker-positive groups (9.6 months vs 5.2 months)
- Reduced treatment-related toxicities in off-target populations
- Higher trial success rate due to enriched enrollment
Such CDx-driven approaches underscore the power of precision medicine.
Clinical Trial Designs Incorporating Stratification
Clinical trial designs increasingly depend on CDx-based stratification:
- Enrichment Design: Includes only biomarker-positive patients
- Stratified Design: Includes all patients but stratifies randomization by biomarker status
- Adaptive Design: Modifies trial conduct based on interim biomarker response
Example Design Table:
| Design Type | Patient Population | CDx Use |
|---|---|---|
| Enrichment | Only EGFR-mutant NSCLC | Screen and enroll mutation-positive |
| Stratified | All NSCLC patients | Randomize by EGFR status |
| Adaptive | Interim subgroup analysis | Modify inclusion criteria based on response |
Explore clinical validation approaches at PharmaValidation.in.
Examples of CDx-Enabled Patient Stratification
HER2 Testing in Breast Cancer: HER2 overexpression detected by IHC or FISH identifies candidates for trastuzumab or pertuzumab. Stratification improves outcomes and reduces cardiotoxicity in non-responders.
PD-L1 Expression in Immunotherapy: PD-L1 IHC assays help stratify patients likely to benefit from immune checkpoint inhibitors like pembrolizumab. Various CDx platforms (e.g., 22C3 pharmDx) have different cutoffs and scoring systems.
ALK Rearrangement in NSCLC: ALK-positive patients benefit from crizotinib. FISH-based CDx testing enables rapid identification and treatment decision-making.
In each of these cases, CDx-driven stratification leads to tailored therapy, faster trial recruitment, and reduced patient risk.
Validation of CDx for Stratification
Validation includes demonstrating analytical performance (LOD, LOQ, specificity) and clinical utility. A typical CDx validation dossier contains:
| Parameter | Acceptable Range |
|---|---|
| Limit of Detection (LOD) | <0.2 ng/mL |
| Precision (Intra-assay CV) | <10% |
| Clinical Sensitivity | >85% |
| Clinical Specificity | >95% |
Proper validation ensures that stratification is based on reliable, reproducible data—essential for regulatory approval and patient safety.
Real-World Application of Stratification in Practice
In the post-approval phase, CDx-based stratification is implemented across clinical settings using standardized lab-developed tests (LDTs) or FDA/CE-approved kits. Challenges include:
- Inter-lab variability
- Turnaround time delays
- Cost and reimbursement variability
- Education of clinicians and patients
Despite these, the use of CDx in real-world stratification is expanding—especially with NGS platforms that assess multiple markers in parallel.
Regulatory guidance on stratification implementation is detailed in FDA guidance documents.
Future Trends in CDx-Based Stratification
Emerging trends include:
- Multi-marker Panels: Combining gene expression, mutation, and protein markers
- Liquid Biopsy: Non-invasive CDx testing from plasma ctDNA
- AI-Driven Stratification: Algorithms using real-world data to refine patient subgroups
- Platform-Based CDx: NGS and multiplex PCR-based stratification tools
For example, FoundationOne CDx provides genomic profiling across 300+ genes to stratify patients for over 30 targeted therapies.
Conclusion
Companion diagnostics have become indispensable tools for patient stratification in both clinical trials and routine care. Their ability to predict therapeutic response transforms treatment paradigms, improves patient outcomes, and accelerates drug development. As diagnostic technology advances, the precision and impact of stratification will only deepen—ushering in the next era of truly personalized medicine.